Skip to Content
  • Previous Rank
    35
  • Revenues ($M)
    $76,450.00
  • Revenue Percent Change
    6.3%
  • Profits ($M)
    $1,300.00
  • Profits Percent Change
    -92.1%
  • Assets ($M)
    $157,303.00
  • Employees
    134,000
  • Market Value — as of March 29, 2018 ($M)
    $343,780.30

The 132-year-old company, which specializes in pharmaceuticals, consumer health care, and medical devices, sells a wide array of health and beauty products including the Johnson’s Baby line, Neutrogena, Listerine, Band Aids, Tylenol, and Motrin. The company has been at the center of lawsuits concerning products that contain talc and their possible link to ovarian cancer and lung-related cancers, and has also been sued in connection with the opioid epidemic. But even amid legal conflicts and competition and pricing pressures in the industry, the company saw domestic sales increase 5.4% and international sales increase 7.4% in 2017. The company raised its sales outlook for 2018 due to the high performance of its pharmaceutical business, particularly cancer drugs.

Company Info

CEO
Alex Gorsky
CEO Title
Chairman & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
New Brunswick, N.J.
Websitehttp://www.jnj.com
Years on Fortune 500 List24
Employees134,000
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Johnson & Johnson Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$76,450.006.3%
Profits ($M)$1,300.00-92.1%
Assets ($M)$157,303.00-
Total Stockholder Equity ($M)$60,160.00-
Market Value — as of March 29, 2018 ($M)$343,780.30-

Profit Ratios

Profit as % of Revenues1.7%
Profits as % of Assets0.8%
Profits as % of Stockholder Equity2.2%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)0.47
EPS % Change (from 2016)-92.1%
EPS % Change (5 year annual rate)-34.4%
EPS % Change (10 year annual rate)-18.5%

Total Return

Total Return to Investors (2017)24.3%
Total Return to Investors (5 year, annualized)18%
Total Return to Investors (10 year, annualized)11%